LASIK for high hyperopia with corneal vertex centration and asymmetric offset yielded a low risk of postoperative higher-order aberrations, according to a study.“Maintaining postoperative keratometry less than 49 D after hyperopic LASIK and centering on the corneal vertex reduces the induction of coma compared to non-aspheric profiles and lower hyperopia,” the study authors said. “The use of corneal vertex centration results in a morphologically stable cornea, less topographic asymmetry and enhanced stability.”
Author: Healio ophthalmology
Publication Exclusive: Repositioning a dislocated IOL can be complicated but have good results
Despite our best efforts, complications happen during cataract surgery, and often it is not surgeon error, but rather weakness or irregularity in the tissue of the patient. When cataract surgery patients do not have a sufficient degree of capsular supp…
STAAR Surgical, Aier Eye Hospital Group enter into strategic cooperation agreement
STAAR Surgical has entered into an agreement with Aier Eye Hospital Group, the largest refractive surgery provider in China, to provide STAAR’s CentraFLOW IOL as a primary and premium option for refractive eye treatment, according to a press release from STAAR. Hospital officials believe that the partnership with STAAR will result in a strong collaboration expected to include surgeon training, clinical studies, patient registries, local inventory, patient information both in person and through digital communications, and an ability to meet patient demand, Li Li, CEO of Aier Eye Hospital Group, (Read more...)
Nerve deficits persist 5 years after cross-linking for keratoconus
Corneal collagen cross-linking did not resolve nerve deficits in keratoconic corneas, according to a study.The observational study included 19 patients with early-stage keratoconus who underwent standard epithelium-off cross-linking and 19 age-matched …
Medicare physician payment: Prepare to ‘MACRA-mize’ your practice
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.It’s been nearly a year since Congress enacted the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, significantly shifting Medicare’s payments to physicians to improve quality and value. The new payment system has two tracks: 1) the Merit-Based Incentive Pay System, or MIPS, and 2) Alternative Payment Models, or APMs. (In case you missed it, background (Read more...)
AngioVue imaging system receives clearance from FDA
The FDA has cleared the AngioVue imaging system, Optovue announced in a press release. The device is now commercially available in the U.S.
Rhopressa maintains lower IOP through 12 months in Rocket 2 registration trial
Rhopressa maintained IOP lowering in patients with glaucoma or ocular hypertension through 12 months in the Rocket 2 phase 3 registration trial, Aerie Pharmaceuticals announced in a press release. Rocket 2 is the second phase 3 registration trial for R…
Alcon to acquire Transcend Medical
Alcon has entered into an agreement to acquire Transcend Medical, Novartis announced in a press release. Transcend Medical has developed a micro-stent to treat mild to moderate glaucoma. The device currently has CE mark approval in Europe and is awaiti…
Seize the day and the future
At the conclusion of the Asia-Pacific Academy of Ophthalmology congress held in conjunction with the All India Ophthalmological Society conference in Hyderabad, India, which brought together more than 9,000 delegates and more than 1,000 invited speaker…
Senate committee proposes more efficient approval of medical devices
The U.S. Senate Committee on Health, Education, Labor and Pensions favorably reported legislation that would streamline the FDA’s evaluation process for medical devices, one of seven biomedical innovation bills currently advancing to the full Senate for consideration.The FDA Device Accountability Act of 2015 (S. 1622), sponsored by Sens. Richard Burr, R-N.C., and Al Franken, D-Minn., and co-sponsored by Mark Kirk, R-Ill., is intended to ensure the “least burdensome means” of evaluating medical devices, according to the bill’s authors.
Protein targets tissue factor, angiogenesis in CNV related to AMD
MIAMI — A protein that targets tissue factor in neovascular age-related macular degeneration was well tolerated in a phase 1 study, a speaker told colleagues here. Carl D. Regillo, MD, reviewed results of a phase 1 study of ICON-1 (Iconic Therapeutics) in the treatment of neovascular AMD at Angiogenesis, Exudation, and Degeneration 2016.
Ocular Therapeutix strategizes design for phase 3 trials of OTX-TP
Ocular Therapeutix is planning to initiate the first of two phase 3 clinical trials of OTX-TP for the treatment of glaucoma and ocular hypertension in the third quarter based on feedback from a recent meeting with the FDA, the company announced in a pr…
Novaliq begins patient enrollment for phase 2 trial of CyclASol for dry eye disease
Novaliq has started to enroll patients in a phase 2 trial of CyclASol to treat dry eye disease, the company announced in a press release. The randomized, double-masked, placebo-controlled multicenter phase 2 trial will evaluate the safety, efficacy and…
Carl Zeiss reports €262.6 million in revenue in first quarter
Carl Zeiss Meditec reported €262.6 million in revenue in the first quarter of the fiscal year compared with €241.1 million reported in the same quarter of the previous fiscal year, according to a press release. Revenue in the Surgical Ophthalmology strategic business unit was reported at €92.6 million in the first quarter, a 13.6% increase from €81.6 million in the same quarter of the previous year.
Wide range of treatments available to optimize ocular surface
The lid margin plays an important role in maintaining ocular surface health. Inflammation of the lid margin in the form of anterior or posterior blepharitis can cause ocular surface inflammation and degrade the quality of the tear film. Before any elec…
Study shows possible genetic link to persistent retinal fluid in AMD
MIAMI — Persistent retinal fluid in eyes that have been treated with anti-VEGFs for neovascular age-related macular degeneration may have a genetic basis, a speaker told colleagues here.“Here we are, basically 10 years after anti-VEGF was introduced, and we’re seeing where the unmet needs are. Only 30%, a third of patients, who are treated gain three lines of vision. That would have been amazing 10 years ago, but we want more. About a third of patients also have persistent fluid after 1 year of treatment,” Philip J. Rosenfeld, MD, PhD, (Read more...)
Iridex receives CE mark for Cyclo G6 laser system in Europe
Iridex has received CE mark to commercialize the Cyclo G6 laser system in Europe for the treatment of glaucoma and its symptoms, the company announced in a press release. The Cyclo G6 laser system is designed to treat a range of glaucoma diseases and features Iridex’s MicroPulse tissue-sparing technology, as well as a family of single-use probes that connect to a laser console.
Senate committee proposes updates to FDA application requirements for reusable devices
In a recent session, the Senate Committee on Health, Education, Labor and Pensions favorably reported a bill requiring manufacturers of reusable medical devices to submit cleaning instructions and validation data to the FDA before bringing these devices to market. The bill also would require the FDA to develop guidance on when manufacturers should seek clearance from the agency before marketing their products.The “Preventing Superbugs and Protecting Patients Act” (S. 2503), sponsored Sen. Patty Murray, D-Wash., references several incidents of drug-resistant infections related to closed-channel duodenoscopes brought to light in the (Read more...)
Publication Exclusive: 29-year-old woman presents with subacute vision loss and headaches
A 29-year-old obese white woman with a known history of idiopathic intracranial hypertension, or IIH, presented to the New England Eye Center with 1 month of progressively decreasing vision in her right eye and positional headaches. She was diagnosed w…
Lampalizumab offers realistic hope for atrophic AMD
Lampalizumab may offer hope for people affected by atrophic age-related macular degeneration. Phase 3 trials are ongoing, and research is focusing on identifying patients who may better respond to the treatment.“We should be grateful for every small step forward, as atrophic AMD is the most difficult form of the disease. In wet AMD we treat to destroy something abnormal, while here we are trying to move forward the internal clock of cells that are programmed to die, which is an infinitely greater challenge,” Jordi Monés, MD, PhD, said in an (Read more...)